(Q44051279)

29 November 2017

Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation (English)

1 reference

29 November 2017

1 reference

International Neoral Renal Transplantation Study Group.

series ordinal

1

1 reference

PubMed ID

12099517

29 November 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

American Journal of Transplantation

29 November 2017

1 reference

29 November 2017

2

1 reference

29 November 2017

2

1 reference

29 November 2017

148-156

1 reference

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

29 November 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Risk factors for chronic rejection in pediatric renal transplant recipients--a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

Factors Influencing the Pharmacokinetics of Cyclosporine in Man

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

The temporal profile of calcineurin inhibition by cyclosporine in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.020206.X

7 January 2021

10.1034/J.1600-6143.2002.020206.X

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

12099517